Navigation Links
Ludwig Institute for Cancer Research and Polaris Group Form Collaboration to Expand Development of Polaris' Novel Cancer Drug, ADI-PEG 20
Date:5/18/2011

NEW YORK and SAN DIEGO, May 18, 2011 /PRNewswire/ -- Ludwig Institute for Cancer Research LTD (LICR) and Polaris Group (Polaris) today announced the formation of a collaboration to expand development of Polaris' novel cancer drug, pegylated arginine deiminase (ADI-PEG 20). ADI-PEG 20 kills tumor cells by depletion of the amino acid arginine.

As part of the collaboration, LICR and Polaris will explore further the potential of ADI-PEG 20 as a cancer therapy and aim to identify other amino acid-degrading enzymes with anti-tumor activity.  The collaboration builds on an existing relationship under which LICR and Polaris have studied ADI-PEG 20 in melanoma and are currently conducting a Phase 2 clinical trial in small cell lung cancer (SCLC) that was initiated in December 2010.  LICR is the sponsor of the SCLC clinical trial, and LICR and Polaris are sharing expenses and resources to conduct this trial.

"We are delighted to have this agreement with Polaris," said Andrew Simpson, Ph.D., Scientific Director of LICR. "This collaboration builds on the work of Lloyd Old, M.D. of LICR and his seminal work on amino acid-degrading enzymes, including asparaginase and arginine deiminase, as anti-cancer treatments. We look forward to continuing our close working relationship with Polaris."

Bor-Wen Wu, Ph.D., Chief Executive Officer of Polaris, said, "This agreement is the fruit of many years of collaboration between LICR and Polaris, and is an opportunity to leverage the strengths of both organizations to attempt to bring ADI-PEG 20 to patients. In particular, I would like to thank Dr. Old for his vision, guidance and dedication to this project, and to his mentoring as we have moved ADI-PEG 20 from pre-clinical studies into human clinical trials."

Dr. Old commented: "The actions of antibodies and enzymes are remarkable for their high degree of specificity, and it is this property that makes them so attractive as potential anti-cancer agents
'/>"/>

SOURCE Polaris Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Polaris Group and The Ludwig Institute for Cancer Research Ltd Initiate Phase 2 Trial of Amino-Acid Degrading Enzyme, ADI-PEG 20, in Patients with Small Cell Lung Cancer
2. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
3. Larta Institute Receives Award for National Institutes of Health Commercialization Assistance Program at 2011 Acquisition, Grants, and Small Business Symposium
4. Van Andel Institute Earns Highest "Green Building" Award
5. LifeNet Health Breaks Ground on New Institute of Regenerative Medicine
6. The Wound Institute® to Feature Educational Forum on Dynamic Reciprocity During the Symposium on Advanced Wound Care and the Wound Healing Society Annual Meeting
7. MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute
8. IBM and The Institute of Bioengineering and Nanotechnology Find Breakthrough for MRSA Treatment
9. Ontario Institute for Cancer Research Announces Investment in Microfluidics Technology for the Discovery of Anti-Cancer Drugs
10. Ontario Institute for Cancer Research Announces Enhancements to its Intellectual Property Development and Commercialization Program
11. Koch Institute for Integrative Cancer Research Dedicated Today
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... that American Indians largely were wiped out by diseases ... brought to the New World by European explorers., One ... lived in the Americas shortly before Europeans arrived, and ... diseases., But new research led by anthropological geneticists Anne ... the University of Tubingen in Germany indicates the diagnosis ...
(Date:8/20/2014)... Group finds that the vascular access device market in ... and China (BRIC) was valued ... of the United States market that year. ... as a result of strong economic expansion, improving access to healthcare ... Resources Group,s coverage of the BRIC vascular access device market: ...
(Date:8/20/2014)... JOSE, Calif. , Aug. 20, 2014 /PRNewswire-iReach/ ... highlights the transformative collaboration between the school,s bioengineering ... As part of the Intel® Software Academic Program, ... computer sciences and the human body.  ... The study exhibits the work of Dr. ...
(Date:8/19/2014)... August 20, 2014 One of ... medicine is an inadequate vascular supply. Nutrient and ... decellularized tissues is critical for successful regeneration and ... to mitigate deficiencies in vascularization and promote angiogenesis ... bioactivity, optimizing scaffold design and architecture, and enhancing ...
Breaking Biology Technology:Unusual discovery leads to fascinating tuberculosis theory 2Unusual discovery leads to fascinating tuberculosis theory 3BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 2BRIC Vascular Access Device Market Valued at $1.6 Billion in 2013, Similar to the U.S. Market 3Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... SEATTLE, Dec. 11 Dendreon Corporation (Nasdaq: DNDN ) ... offering have exercised in full their option to purchase an ... price of $24.75 per share. The exercise of the ... of 17,250,000 shares of common stock. Dendreon expects to ...
... , SAN DIEGO, Dec. 11 Ambit ... Texas M. D. Anderson Cancer Center of the first patient in the ... Phase 2 pivotal trial in patients with relapsed or refractory acute myeloid ... selective small molecule that was specifically designed as a FMS-like tyrosine kinase-3 ...
... 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY ... of Dr. Alan Warrander to the role of Senior ... Warrander will be responsible for the execution of the ... President and CEO of Oncolytics. "Having reached an agreement ...
Cached Biology Technology:Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3
(Date:8/21/2014)... A landmark study aimed at improving the food intake, ... long-term care homes is among three projects at the ... grants from the Canadian Institutes of Health Research (CIHR). ... Applied Health Sciences at Waterloo, and a Schlegel research ... two years to investigate why many Canadians living in ...
(Date:8/21/2014)... Saturday to Wednesday, Oct. 18-22, 2014 , ... Harbor Drive, San Diego, CA 92101 , ... other presentations of the latest research in human ... session featuring high-scoring abstracts on rare genetic variants ... cancers, and treatment for sun sensitivity (Saturday, Oct. ...
(Date:8/21/2014)... Researchers from North Carolina State University have developed a ... The model has applications for creating new materials as ... , "Our new technique allows us to model much ... so much more quickly," says Nan Li, lead author ... student in NC State,s Department of Materials Science and ...
Breaking Biology News(10 mins):Grants will fund landmark aging research at Waterloo 2American Society of Human Genetics 2014 Annual Meeting 2Researchers develop models to study polyelectrolytes, including DNA and RNA 2
... NOAA/Virginia Sea Grant has awarded Virginia Tech $119,000 to ... virus in both shucked and unshucked oysters. , The ... High Pressure Processing Laboratory, and Laura Douglas, lab manager, ... schedules. The laboratory is a facility of the Department ...
... a new protein that plays a critical role in enabling ... or stress, as well as in the progressive loss of ... Their findings, they said, suggest new approaches to prevent or ... in the U.S. The team reports its findings in the ...
... lifespan in yeast, worms, and flies keeps blood sugar ... the August Cell Metabolism. The findings suggest therapeutic interventions ... as type 2 diabetes, which frequently arise with age, ... with an excess of the protein Sirt1 in cells ...
Cached Biology News:Use of high hydrostatic pressure to inactivate Hepatitis A virus in oysters studied 2Newly Discovered Role for Heart Response Enzyme May Yield Better Heart Failure Therapy 2Life-extending protein keeps blood sugar in check 2
... Protein Purification Plates are designed for quick ... The 96-well plates feature two 0.25mm holes ... each well. The wells remain liquid-tight during ... during which time the protein diffuses from ...
... the state-of-the-art in permanent mounting media. ... preservation of immunohistochemical organic insoluble substrates ... New Fuchsin, and any other organic ... sections. Clarin can be used for ...
... industry's first siRNA sequence design software in ... these tools consistent with new experimental strategies ... of RNAi. With the introduction of ... tools, OligoEngine is pleased to offer the ...
... been designed and created in order to ... genotyping analysis tool. We incorporated the suggestions ... the software. Their main requirements were ease- ... acquisition cost. GeneMarker can perform analysis ...
Biology Products: